

Nubeqa[®] (darolutamide) – Expanded indication

- On August 5, 2022, the <u>FDA announced</u> the approval of Bayer's <u>Nubeqa (darolutamide)</u>, for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with <u>docetaxel</u>.
 - Nubeqa was previously approved for the treatment of adult patients with_non-metastatic castration-resistant prostate cancer (mCRPC).
- The approval of Nubeqa for the expanded indication was based on ARASENS, a double-blind, placebo-controlled study in 1,306 patients with mHSPC. Patients received Nubeqa 600 mg orally twice daily or placebo, concomitantly with docetaxel for 6 cycles. The major efficacy outcome measure was overall survival (OS).
 - The OS was not reached (NR) (95% CI: NR, NR) in the Nubeqa group vs. 48.9 months (95% CI: 44.4, NR) in the placebo group (Hazard ratio 0.68; 95% CI: 0.57, 0.80; p < 0.0001).
- The most common adverse reactions (≥ 10% with a ≥ 2% increase over placebo with docetaxel) with Nubeqa use in mHSPC were constipation, decreased appetite, rash, hemorrhage, weight increased, and hypertension.
- The most common laboratory test abnormalities (≥ 30%) with Nubeqa use in mHSPC were anemia, hyperglycemia, decreased lymphocyte count, decreased neutrophil count, increased aspartate transferase, increased alanine transaminase, and hypocalcemia.
- The recommended dose of Nubeqa for the treatment of mHSPC and mCRPC is 600 mg (two 300 mg tablets) taken orally, twice daily, with food.
 - For patients with mHSPC treated with Nubeqa in combination with docetaxel, administer the first of 6 cycles of docetaxel within 6 weeks after the start of Nubeqa treatment.
 - Refer to docetaxel prescribing information for additional dosing information.
 - Treatment with Nubeqa should be continued until disease progression or unacceptable toxicity occurs.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.